Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in... Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. 더 보기
– Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – –...
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate...
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...
– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.35 | -12.7478753541 | 10.59 | 10.64 | 8.6 | 320454 | 9.55023336 | CS |
4 | -2.59 | -21.8934911243 | 11.83 | 13.43 | 8.6 | 280872 | 11.37474795 | CS |
12 | -4.5 | -32.7510917031 | 13.74 | 15.25 | 8.6 | 226910 | 12.56886825 | CS |
26 | -5.325 | -36.5602471679 | 14.565 | 15.25 | 8.58 | 190703 | 12.38123675 | CS |
52 | 0.82 | 9.73871733967 | 8.42 | 16.905 | 7.95 | 186847 | 12.67246213 | CS |
156 | -11.86 | -56.2085308057 | 21.1 | 21.98 | 5.85 | 188942 | 12.81377903 | CS |
260 | -11.86 | -56.2085308057 | 21.1 | 21.98 | 5.85 | 188942 | 12.81377903 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관